Barclays Maintains Overweight on Iovance Biotherapeutics, Lowers Price Target to $5

Benzinga · 04/14/2025 19:52
Barclays analyst Peter Lawson maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and lowers the price target from $22 to $5.